Skip to main content
SpringerLink
Log in

Drug Treatment for Obesity in the Post-Sibutramine Era

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Obesity is a major health problem worldwide. It is associated with cardiovascular diseases, diabetes mellitus and decreased longevity. In managing obesity, diet and exercise are essential; pharmacological therapy may be added for obese patients or overweight patients with cardiovascular risk factors. Sibutramine is a serotonergic and adrenergic drug that reduces food intake and increases thermogenesis. It reduces bodyweight by about 4.2 kg after 12 months, and improves blood glucose and lipids; however, it can increase heart rate and blood pressure. In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market. The lesson learnt from this is the importance of patient selection, limiting the duration of treatment and stopping treatment in non-responders. Currently, phentermine and amfepramone (diethylpropion) are approved for short-term treatment of obesity (up to 3 months) and orlistat is approved for longer-term treatment; however, the gastrointestinal adverse effects of orlistat may be intolerable for some patients. There is now a clear need to find anti-obesity drugs that are effective and safe in the long term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010; 303(3): 235–41

    Article  PubMed  CAS  Google Scholar 

  2. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003; 11: 1223–31

    Article  PubMed  Google Scholar 

  3. Kopelman P. Health risks associated with overweight and obesity. Obes Rev 2007; 8 Suppl. 1: 13–7

    Article  PubMed  Google Scholar 

  4. Hubert H, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968–77

    Article  PubMed  CAS  Google Scholar 

  5. Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293(15): 1861–7

    Article  PubMed  CAS  Google Scholar 

  6. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790–7

    Article  PubMed  CAS  Google Scholar 

  7. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking US white women aged 40–64 years. Am J Epidemiol 1995; 141: 1128–41

    PubMed  CAS  Google Scholar 

  8. Tuomilehto J, Lindström J, Eriksson JG, et al., for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50

    Article  PubMed  CAS  Google Scholar 

  9. Padwal RS, Rucker D, Li SK, et al. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003; (4): CD004094

  10. Oude Luttikhuis H, Baur L, Jansen H, et al. Interventions for treating obesity in children. Cochrane Database Syst Rev 2009; (1): CD001872

  11. Norris SL, Zhang X, Avenell A, et al. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; (1): CD004096

  12. Siebenhofer A, Horvath K, Jeitler K, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev 2009; (3): CD007654

  13. Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142: 525–31

    PubMed  Google Scholar 

  14. World Health Organization. Global strategy on diet, physical activity and health [online]. Available from URL: http://www.who.int/gb/ebwha/pdf_files/WHA57/A57_R17-en.pdf [Accessed 2010 May 3]

  15. Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring) 2009; 17 Suppl. 3: S43–8

    Article  Google Scholar 

  16. Bravata DM, Sanders L, Huang J, et al. Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA 2003; 289: 1837–50

    Article  PubMed  CAS  Google Scholar 

  17. Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348: 2074–81

    Article  PubMed  CAS  Google Scholar 

  18. Yancy Jr WS, Olsen MK, Guyton JR, et al. A low carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004; 140: 769–77

    PubMed  Google Scholar 

  19. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117–24

    Article  PubMed  CAS  Google Scholar 

  20. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1): 3–10

    Article  PubMed  CAS  Google Scholar 

  21. Appel LJ, Sacks FM, Carey VJ, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids. OmniHeart Collaborative Research Group. JAMA 2005; 294: 2455–64

    Article  PubMed  CAS  Google Scholar 

  22. Curioni CC, Lourenco PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 2005; 29: 1168–74

    Article  CAS  Google Scholar 

  23. Brown T, Avenell A, Edmunds LD, et al. Systematic review of long-term lifestyle interventions to prevent weight gain and morbidity in adults. Obes Rev 2009; 10(6): 627–38

    Article  PubMed  CAS  Google Scholar 

  24. Robinson TN. Reducing children’s television viewing to prevent obesity: a randomized controlled trial. JAMA 1999; 282: 1561–7

    Article  PubMed  CAS  Google Scholar 

  25. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994–1003

    Article  PubMed  CAS  Google Scholar 

  26. Rucker D, Padwal R, Li SK, et al. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194–9

    Article  PubMed  CAS  Google Scholar 

  27. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397–415

    PubMed  CAS  Google Scholar 

  28. Van Gaal LF, Wauters MA, de Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21: S5–9

    PubMed  Google Scholar 

  29. Li M, Cheung B. Pharmacotherapy for obesity. Br J Clin Pharmacol 2009; 68: 804–10

    Article  PubMed  CAS  Google Scholar 

  30. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26(14): 1027–48

    Article  PubMed  CAS  Google Scholar 

  31. Chung JY, Jang SB, Lee YJ, et al. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 2011; 51(1): 53–9

    Article  PubMed  CAS  Google Scholar 

  32. Levin BE, Dunn-Meynell AA. Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol 2000; 279(6): R2222–8

    PubMed  CAS  Google Scholar 

  33. Rolls BJ, Shide DJ, Thorwart ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 6: 1–11

    Article  PubMed  CAS  Google Scholar 

  34. Hansen DL, Toubro S, Stock MJ, et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180–6

    PubMed  CAS  Google Scholar 

  35. Fanghanel G, Cortinas L, Sanchez Reyes L, et al. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes 2000; 24: 144–50

    Article  CAS  Google Scholar 

  36. Cuellar GEM, Ruiz AM, Monsalve MCR, et al. Six-month treatment of obesity with sibutramine 15mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71–82

    Article  PubMed  CAS  Google Scholar 

  37. Gokcel A, Karakose H, Ertorer EM, et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24(11): 1957–60

    Article  PubMed  CAS  Google Scholar 

  38. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002; 19(2): 119–24

    Article  PubMed  CAS  Google Scholar 

  39. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26(1): 125–31

    Article  PubMed  CAS  Google Scholar 

  40. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093–124

    Article  PubMed  CAS  Google Scholar 

  41. James WPT, Astrup A, Finer N, et al., for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119–25

    Article  PubMed  CAS  Google Scholar 

  42. Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am JMed 1999; 106: 179–84

    CAS  Google Scholar 

  43. Cole JO, Levin A, Beake B, et al. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998; 18: 231–6

    Article  PubMed  CAS  Google Scholar 

  44. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283: 1703–9

    Article  PubMed  CAS  Google Scholar 

  45. Jordan J, Scholze J, Matiba B, et al. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord 2005; 29: 509–16

    CAS  Google Scholar 

  46. Nakou E, Filippatos TD, Liberopoulos EN, et al. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008; 9: 1629–39

    Article  PubMed  CAS  Google Scholar 

  47. Johansson K, Sundström J, Neovius K, et al. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev 2009; 11(11): 777–91

    Article  Google Scholar 

  48. Heusser K, Tank J, Diedrich A, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006; 79: 500–8

    Article  PubMed  CAS  Google Scholar 

  49. Torp-Pedersen C, Caterson I, Coutinho W, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. SCOUT Investigators. Eur Heart J 2007; 28: 2915–23

    Article  PubMed  Google Scholar 

  50. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. SCOUT Investigators. N Engl J Med 2010; 363(10): 905–17

    Article  PubMed  CAS  Google Scholar 

  51. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010; 340: c824

    Article  PubMed  Google Scholar 

  52. US FDA. FDA drug safety communication: FDA recommends against the continued use of Meridia (sibutramine) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm [Accessed 2010 Dec 9]

  53. Finer N, Executive Steering Committee of the Sibutramine Cardiovascular Outcome Trial. Withdrawal of sibutramine: editorial is judgment in advance of the facts. BMJ 2010 Mar 10; 340: c1346

    Article  PubMed  Google Scholar 

  54. Gregg EW, Gerzoff RB, Thompson TJ, et al. Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 2003 Mar 4; 138(5): 383–9

    PubMed  Google Scholar 

  55. Meridia® (sibutramine hydrochloride monohydrate) capsules CS-IV [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DrugSafety/PublicHealthAdvisories/UCM130745.pdf [Accessed 2010 May 3]

  56. Morse SA, Gulati R, Reisin E. The obesity paradox and cardiovascular disease. Curr Hypertens Rep 2010; 12(2): 120–6

    Article  PubMed  Google Scholar 

  57. von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? Eur Heart J 2007; 28(23): 2830–1

    Article  Google Scholar 

  58. Hsiao TJ, Wu LS, Hwang Y, et al. Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population. Mol Diagn Ther 2010 Apr 1; 14(2): 101–6

    Article  PubMed  CAS  Google Scholar 

  59. Garrow JS. Withdrawal of sibutramine: magic bullets now uncontrolled. BMJ 2010 Mar 10; 340: c1351

    Article  PubMed  Google Scholar 

  60. Tang MH, Chen SP, Ng SW, et al. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J Clin Pharmacol 2011; 71(2): 250–3

    Article  PubMed  Google Scholar 

  61. Smith FJ, Holman CD, Moorin RE, et al. Incidence of bariatric surgery and postoperative outcomes: a population-based analysis in Western Australia. Med J Aust 2008; 189: 198–202

    PubMed  Google Scholar 

  62. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683–93

    Article  PubMed  Google Scholar 

  63. Mohammed BS, Cohen S, Reeds D, et al. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease. Obesity 2008; 16: 2645–51

    Article  Google Scholar 

  64. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21: S12–23

    PubMed  CAS  Google Scholar 

  65. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532–46

    PubMed  CAS  Google Scholar 

  66. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–61

    Article  PubMed  CAS  Google Scholar 

  67. Shi YF, Pan CY, Hill J, et al. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. Diabetic Med 2005; 22: 1737–43

    Article  PubMed  CAS  Google Scholar 

  68. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 2873–83

    Article  PubMed  CAS  Google Scholar 

  69. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002; 22(7): 814–22

    Article  PubMed  CAS  Google Scholar 

  70. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010 Mar; 123 (3 Suppl.): S28–37

    Article  PubMed  CAS  Google Scholar 

  71. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. NN8022-1807 Study Group. Lancet 2009 Nov 7; 374(9701): 1606–16

    Article  PubMed  CAS  Google Scholar 

  72. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; (2): CD006739

  73. Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 2007 Aug; 293(2): E620–7

    Article  PubMed  CAS  Google Scholar 

  74. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007 Aug; 92(8): 2977–83

    Article  PubMed  CAS  Google Scholar 

  75. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors. Lancet 2005; 365: 1363–4

    Article  PubMed  Google Scholar 

  76. Van Gaal LF, Rissanen AM, Scheen AJ, et al., for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–97

    Article  PubMed  Google Scholar 

  77. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al., for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761–75

    Article  PubMed  CAS  Google Scholar 

  78. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Rimonabant in Obesity-Lipids Study Group. N Engl J Med 2005; 353: 2121–34

    Article  PubMed  CAS  Google Scholar 

  79. European Medicines Agency. The European Medicines Agency recommends suspension of the marketing authorization of Acomplia [press release]. 2008 Oct 23 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014774.pdf [Accessed 2011 May 4]

  80. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006; 5: 919–31

    Article  PubMed  CAS  Google Scholar 

  81. Melnikova I, Wages D. Anti-obesity therapies. Nat Rev Drug Discov 2006; 5: 369–70

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

There was no specific funding for the preparation of this review. The author has no conflicts of interest to declare that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong

    Bernard M.Y. Cheung

Authors
  1. Bernard M.Y. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard M.Y. Cheung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheung, B.M. Drug Treatment for Obesity in the Post-Sibutramine Era. Drug-Safety 34, 641–650 (2011). https://doi.org/10.2165/11592040-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11592040-000000000-00000

Keywords

Search

Navigation